1 August 2014

Contents

Editorial

• July/August 2014: Volume 15 Number 7/8

Conference reports

• 20th International AIDS Conference, 20-25 July 2014, Melbourne

• The loss of friends and colleagues from flight MH 17

• Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

• Pill A, Pill B: simplified second-line treatment for low-income countries

• UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030

• No difference in overall anaemia rate with reduced dose AZT

• Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

• Cure research at IAS 2014: TILDA measures the reservoir and romidepsin wakes it up

• HIV and transgender issues at AIDS 2014

• Transgender services and clinics: interviews at AIDS 2014 with JoAnne Keatley and Beatriz Grinsztejn

• Publications launched at AIDS 2014

• 6th International Workshop on HIV Paediatrics, 18-19 July 2014, Melbourne

• Update on paediatric antiretrovirals

• Is d4T a viable option for children in low-income countries?

• 3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

• Rationalising the paediatric antiretroviral formulary in Malawi

• Time to first-line failure in the IeDEA cohort

• Influence of early ART on antibody detection in children

• 8th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Poor Settings (INTEREST), 5-6 May 2014, Lusaka, Zambia

• Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia

• Pregnancy outcomes in Zambia

• Uptake of ART is influenced by distance to the health facility in rural Zambia

• Genotyping using dried blood spots in rural South African setting

Antiretrovirals

• Dolutegravir-based single-tablet regimen set for EU approval

Treatment access

• New ARV prescribing guidelines for London (2014)

Paediatric care

• Wrestling with the implications of the Mississippi case

Guidelines

• WHO guidelines for key populations (July 2014): gay men, people who inject drugs, people in prisons, sex workers, transgender people

• EASL update guidelines for hepatitis C (April 2014)

Side effects

• Bone mineral density linked to inflammatory markers in HIV positive people who are ART naïve

Hepatitis coinfection

• US Senate investigate Gilead for sofosbuvir price: potential to bankrupt Federal healthcare and add $300 annually to every American insurance premium for the next five years

Cure-related research

• Effects of long-term ART initiated during primary HIV infection on reservoir size

Basic science and immunology

• Molecular events in HIV neutralising antibody development

On the web

• Community reports and briefings

• Online journals

PDFs

• Volume 15 Number 7/8 July/August 2014 PDF